Cargando…

The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes

The purpose of this study was to investigate the short-term efficacy and safety of autologous platelet-rich plasma (a-PRP) as an adjuvant to revisional vitrectomy for refractory full-thickness macular holes (rFTMHs). We conducted a prospective, non-randomized interventional study including patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Buzzi, Matilde, Parisi, Guglielmo, Marolo, Paola, Gelormini, Francesco, Ferrara, Mariantonia, Raimondi, Raffaele, Allegrini, Davide, Rossi, Tommaso, Reibaldi, Michele, Romano, Mario R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004127/
https://www.ncbi.nlm.nih.gov/pubmed/36902837
http://dx.doi.org/10.3390/jcm12052050
_version_ 1784904757249310720
author Buzzi, Matilde
Parisi, Guglielmo
Marolo, Paola
Gelormini, Francesco
Ferrara, Mariantonia
Raimondi, Raffaele
Allegrini, Davide
Rossi, Tommaso
Reibaldi, Michele
Romano, Mario R.
author_facet Buzzi, Matilde
Parisi, Guglielmo
Marolo, Paola
Gelormini, Francesco
Ferrara, Mariantonia
Raimondi, Raffaele
Allegrini, Davide
Rossi, Tommaso
Reibaldi, Michele
Romano, Mario R.
author_sort Buzzi, Matilde
collection PubMed
description The purpose of this study was to investigate the short-term efficacy and safety of autologous platelet-rich plasma (a-PRP) as an adjuvant to revisional vitrectomy for refractory full-thickness macular holes (rFTMHs). We conducted a prospective, non-randomized interventional study including patients with rFTMH after a pars plana vitrectomy (PPV) with internal limiting membrane peeling and gas tamponade. We included 28 eyes from 27 patients with rFTMHs: 12 rFTMHs in highly myopic eyes (axial length greater than 26.5 mm or a refractive error greater than -6D or both); 12 large rFTMHs (minimum hole width > 400 μm); and 4 rFTMHs secondary to the optic disc pit. All patients underwent 25-G PPV with a-PRP, a median time of 3.5 ± 1.8 months after the primary repair. At the six-month follow-up, the overall rFTMH closure rate was 92.9%, distributed as follows: 11 out of 12 eyes (91.7%) in the highly myopic group, 11 out of 12 eyes (91.7%) in the large rFTMH group, and 4 out of 4 eyes (100%) in the optic disc pit group. Median best-corrected visual acuity significantly improved in all groups, in particular from 1.00 (interquartile range: 0.85 to 1.30) to 0.70 (0.40 to 0.85) LogMAR in the highly myopic group (p = 0.016), from 0.90 (0.70 to 1.49) to 0.40 (0.35 to 0.70) LogMAR in the large rFTMH group (p = 0.005), and from 0.90 (0.75 to 1.00) to 0.50 (0.28 to 0.65) LogMAR in the optic disc pit group. No intraoperative or postoperative complications were reported. In conclusion, a-PRP can be an effective adjuvant to PPV in the management of rFTMHs.
format Online
Article
Text
id pubmed-10004127
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100041272023-03-11 The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes Buzzi, Matilde Parisi, Guglielmo Marolo, Paola Gelormini, Francesco Ferrara, Mariantonia Raimondi, Raffaele Allegrini, Davide Rossi, Tommaso Reibaldi, Michele Romano, Mario R. J Clin Med Article The purpose of this study was to investigate the short-term efficacy and safety of autologous platelet-rich plasma (a-PRP) as an adjuvant to revisional vitrectomy for refractory full-thickness macular holes (rFTMHs). We conducted a prospective, non-randomized interventional study including patients with rFTMH after a pars plana vitrectomy (PPV) with internal limiting membrane peeling and gas tamponade. We included 28 eyes from 27 patients with rFTMHs: 12 rFTMHs in highly myopic eyes (axial length greater than 26.5 mm or a refractive error greater than -6D or both); 12 large rFTMHs (minimum hole width > 400 μm); and 4 rFTMHs secondary to the optic disc pit. All patients underwent 25-G PPV with a-PRP, a median time of 3.5 ± 1.8 months after the primary repair. At the six-month follow-up, the overall rFTMH closure rate was 92.9%, distributed as follows: 11 out of 12 eyes (91.7%) in the highly myopic group, 11 out of 12 eyes (91.7%) in the large rFTMH group, and 4 out of 4 eyes (100%) in the optic disc pit group. Median best-corrected visual acuity significantly improved in all groups, in particular from 1.00 (interquartile range: 0.85 to 1.30) to 0.70 (0.40 to 0.85) LogMAR in the highly myopic group (p = 0.016), from 0.90 (0.70 to 1.49) to 0.40 (0.35 to 0.70) LogMAR in the large rFTMH group (p = 0.005), and from 0.90 (0.75 to 1.00) to 0.50 (0.28 to 0.65) LogMAR in the optic disc pit group. No intraoperative or postoperative complications were reported. In conclusion, a-PRP can be an effective adjuvant to PPV in the management of rFTMHs. MDPI 2023-03-04 /pmc/articles/PMC10004127/ /pubmed/36902837 http://dx.doi.org/10.3390/jcm12052050 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Buzzi, Matilde
Parisi, Guglielmo
Marolo, Paola
Gelormini, Francesco
Ferrara, Mariantonia
Raimondi, Raffaele
Allegrini, Davide
Rossi, Tommaso
Reibaldi, Michele
Romano, Mario R.
The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes
title The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes
title_full The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes
title_fullStr The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes
title_full_unstemmed The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes
title_short The Short-Term Results of Autologous Platelet-Rich Plasma as an Adjuvant to Re-Intervention in the Treatment of Refractory Full-Thickness Macular Holes
title_sort short-term results of autologous platelet-rich plasma as an adjuvant to re-intervention in the treatment of refractory full-thickness macular holes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004127/
https://www.ncbi.nlm.nih.gov/pubmed/36902837
http://dx.doi.org/10.3390/jcm12052050
work_keys_str_mv AT buzzimatilde theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT parisiguglielmo theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT marolopaola theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT gelorminifrancesco theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT ferraramariantonia theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT raimondiraffaele theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT allegrinidavide theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT rossitommaso theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT reibaldimichele theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT romanomarior theshorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT buzzimatilde shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT parisiguglielmo shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT marolopaola shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT gelorminifrancesco shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT ferraramariantonia shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT raimondiraffaele shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT allegrinidavide shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT rossitommaso shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT reibaldimichele shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes
AT romanomarior shorttermresultsofautologousplateletrichplasmaasanadjuvanttoreinterventioninthetreatmentofrefractoryfullthicknessmacularholes